Literature DB >> 17070526

Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7.

Ziad Dahabreh1, Rozalia Dimitriou, Peter V Giannoudis.   

Abstract

OBJECTIVE: To compare the cost implications of treatment of persistent fracture non-unions before and after application of recombinant human bone morphogenetic protein-7 (BMP-7).
METHOD: Of 25 fracture non-unions, 9 were treated using BMP-7 alone and 16 using BMP-7 and bone grafting. These patients were prospectively followed up, and the costs incurred were analysed.
RESULTS: The mean number of procedures per fracture performed before application of BMP-7 was 4.16, versus 1.2 thereafter. Mean hospital stay and cost of treatment per fracture before receiving BMP-7 were 26.84 days and pound 13,844.68, versus 7.8 days and pound 7338.4 thereafter. The overall cost of treatment of persistent fracture non-unions with BMP-7 was 47.0% less than that of the numerous previous unsuccessful treatments (p=0.001).
CONCLUSIONS: Treating fracture non-unions is costly, but this could be reduced by early BMP-7 administration when a complex or persistent fracture non-union is present or anticipated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070526     DOI: 10.1016/j.injury.2006.08.055

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  27 in total

1.  Stability differentials for proximal vs distal fusion of total hip arthroplasty femoral impaction grafts.

Authors:  Anneliese D Heiner; John J Callaghan; Thomas D Brown
Journal:  J Arthroplasty       Date:  2008-01-24       Impact factor: 4.757

2.  [Osteoblasts : cellular and molecular regulatory mechanisms in fracture healing].

Authors:  A Hofmann; S G Mattyasovszky; C Brüning; U Ritz; I Mehling; A Meurer; P M Rommens
Journal:  Orthopade       Date:  2009-11       Impact factor: 1.087

3.  Clinical application of recombinant human bone morphogenetic protein in cats and dogs: a review of 13 cases.

Authors:  Cory B Pinel; G Elizabeth Pluhar
Journal:  Can Vet J       Date:  2012-07       Impact factor: 1.008

Review 4.  Bone morphogenetic protein (BMP) for fracture healing in adults.

Authors:  Kimberly R Garrison; Ian Shemilt; Simon Donell; Jonathan J Ryder; Miranda Mugford; Ian Harvey; Fujian Song; Volker Alt
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

5.  Comparative study suggests that human bone morphogenetic proteins have no influence on the outcome of operative treatment of aseptic clavicle non-unions.

Authors:  Christian von Rüden; Mario Morgenstern; Jan Friederichs; Peter Augat; Simon Hackl; Alexander Woltmann; Volker Bühren; Christian Hierholzer
Journal:  Int Orthop       Date:  2016-08-13       Impact factor: 3.075

6.  A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7.

Authors:  Z Dahabreh; G M Calori; N K Kanakaris; V S Nikolaou; P V Giannoudis
Journal:  Int Orthop       Date:  2008-12-04       Impact factor: 3.075

7.  The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions.

Authors:  Peter V Giannoudis; Nikolaos K Kanakaris; Rozalia Dimitriou; Ian Gill; Vinod Kolimarala; Richard J Montgomery
Journal:  Clin Orthop Relat Res       Date:  2009-04-24       Impact factor: 4.176

8.  [Operative management of clavicular non-union : Iliac crest bone graft and anatomic locking compression plate].

Authors:  C Kirchhoff; I J Banke; M Beirer; A B Imhoff; P Biberthaler
Journal:  Oper Orthop Traumatol       Date:  2013-09-22       Impact factor: 1.154

9.  Silk Biomaterials-Mediated miRNA Functionalized Orthopedic Devices.

Authors:  Eric N James; Emily Van Doren; Chunmei Li; David L Kaplan
Journal:  Tissue Eng Part A       Date:  2018-08-22       Impact factor: 3.845

10.  Adenovirus-mediated bone morphogenetic protein-2 promotes osteogenic differentiation in human mesenchymal stem cells in vitro.

Authors:  Hong Cao; Zhi-Bo Sun; Lei Zhang; Wei Qian; Chun-Yang Li; Xiao-Peng Guo; Ying Zhang
Journal:  Exp Ther Med       Date:  2017-05-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.